Clinical data | |
---|---|
Trade names | Phtorazisin |
Other names | Fluoracizine; Fluoracyzine; Fluoracisine; Ftoracizin; Ftoracizine; Phthoracizin[1][2] |
Routes of administration | Oral, intramuscular injection |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H21F3N2OS |
Molar mass | 394.46 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Fluacizine, sold under the brand name Phtorazisin, is a tricyclic antidepressant (TCA) of the phenothiazine group which is or was marketed in Russia.[1][2][3] Unlike other phenothiazines, fluacizine is not an antipsychotic, and can actually reverse catalepsy and extrapyramidal symptoms induced by antidopaminergic agents like antipsychotics, reserpine, and tetrabenazine as well as potentiate amphetamine-induced stereotypy.[3] It is known to act as a norepinephrine reuptake inhibitor, antihistamine, and anticholinergic.[4][5][6][7][3] The drug was developed in the 1960s and was marketed in the 1970s.[1][4] It is the trifluoromethyl analogue of chloracizine.[7]